ALNY

Alnylam Pharmaceuticals Inc.

Price

$265.23

return (12m)

-41.52%

p/e

40.56

p/bv

24.20

DIVIDEND YIELD

0.00%

ALNY price

Alnylam Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALNY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

17.29%

3 months

-12.48%

1 year

-41.52%

2 years

5.47%

5 years

40.88%

10 years

265.68%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ALNY

Valuation

P/E

40.56

Sector -4.23

Industry -4.23

P/BV

24.20

Sector 2.11

Industry 2.11

P/Revenue (PSR)

6.82

Sector 2.05

Industry 2.05

EV/EBITDA

131.82

Sector -546.75

Industry -546.75

EV/EBIT

140.25

Sector -37.85

Industry -37.85

P/EBITDA

50.71

Sector -51.33

Industry -51.33

P/EBIT

55.40

Sector -39.56

Industry -39.56

P/Total Assets

5.90

Sector 1.25

Industry 1.25

P/Net Current Assets

78.86

Sector -5.36

Industry -5.36

P/Working Capital

10.54

Sector -1.24

Industry -1.24

EPS

5.84

Sector -1.92

Industry -1.92

BVPS

9.79

Sector 1.93

Industry 1.93

Efficiency

Gross Margin

79.72%

Sector 39.10%

Industry 39.10%

EBITDA Margin

17.91%

Sector -13,872.36%

Industry -13,872.36%

EBIT Margin

16.83%

Sector -4,235,733.26%

Industry -4,235,733.26%

Operating Margin

20.81%

Sector -36.62%

Industry -36.62%

Net Profit Margins

16.82%

Sector -37.41%

Industry -37.41%

Asset Turnover

0.23

Sector 0.03

Industry 0.03

Profitability

ROE

59.67%

Sector -60.49%

Industry -60.49%

ROA

14.54%

Sector -63.06%

Industry -63.06%

ROIC

Sector -498.28%

Industry -498.28%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.05

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-9.94

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

-10.57

Sector -10.24

Industry -10.24

Net Debt / Equity

-1.70

Sector -38,821.65

Industry -38,821.65

Gross Debt / Equity

0.75

Sector -0.83

Industry -0.83

Equity/Assets

0.24

Sector 0.43

Industry 0.43

Liabilities/Assets

0.76

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

41.59%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals ALNY

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Alnylam Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$265.23

Fair Value

$35.87

Upside Return potential.

-86.48%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ALNY Alnylam Pharmaceuticals Inc.	$265.23	-40.72%	0.00%	40.56	24.20	59.67%	16.82%
JNJ Johnson & Johnson	$276.47	60.00%	1.98%	30.34	7.51	24.76%	21.48%
PFE Pfizer Inc.	$28.64	23.67%	6.28%	35.72	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$257.20	25.27%	2.66%	72.02	-76.66	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.74	-12.60%	4.06%	11.16	5.92	53.11%	35.32%
MRK Merck & Co. Inc.	$150.67	85.97%	2.29%	114.53	8.64	7.55%	4.76%
AZN AstraZeneca PLC	$162.57	1.81%	1.99%	23.89	4.95	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.95	47.63%	3.79%	14.60	6.06	41.55%	18.85%
ZTS Zoetis Inc.	$75.67	-49.40%	2.68%	12.14	10.20	84.02%	27.77%
AMGN Amgen Inc.	$438.54	60.04%	2.28%	26.55	19.86	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$834.48	47.70%	0.58%	18.86	2.57	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.01	47.03%	0.00%	29.70	85.59	288.14%	24.86%
MCK McKesson Corporation	$917.36	33.47%	0.37%	20.12	-27.60	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$551.38	39.02%	0.00%	31.27	6.80	21.76%	35.00%
CAH Cardinal Health Inc.	$247.79	66.68%	0.87%	35.62	-20.64	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$42.15	12.31%	0.00%	12.57	2.28	18.14%	18.89%
ARGX argenx SE	$1,038.19	43.79%	0.00%	3.11	3.48	112.18%	44.41%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALNY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (7 people)

United States

23 years

Founded: 2003

2004

Time since IPO - 22 years

1.453

Employees

Alnylam Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $32.77 billion, with shareholders equity totaling $1.35 billion.

The company employs approximately 1.453 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Alnylam Pharmaceuticals Inc. reported $4.80 billion in revenue, generating net income of $807.99 million.

Key financial metrics include a P/E ratio of 40.56, a price-to-book (P/B) ratio of 24.20, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALNY.

Market cap

$32.77 billion

Net worth

$1.35 billion

$1,354,118,000.00

Assets

$5.56 billion

$5,558,769,000.00

Total Shares Outstanding

138.25 million

138,249,000

Average Daily Trading Volume

$1.15 million

$1,150,870.00

Sector

Health Care

Industry

Biotechnology

ALNY

revenue by Business Segment Alnylam Pharmaceuticals

Revenue by Region Alnylam Pharmaceuticals

ALNY revenue and profits

Financial Results ALNY

DRAG THE FRAME TO SEE MORE DATA

ALNY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$917.36 34,14% (12M)

P/E

20.12

0.37%

ROE

-137.16%

P/BV

-27.60

CAH - Cardinal Health

$247.79 67,79% (12M)

P/E

35.62

0.87%

ROE

-57.93%

P/BV

-20.64

JNJ - Johnson & Johnson

$276.47 59,62% (12M)

P/E

30.34

1.98%

ROE

24.76%

P/BV

7.51

ABBV - AbbVie

$257.20 24,86% (12M)

P/E

72.02

2.66%

ROE

-106.44%

P/BV

-76.66

MRK - Merck & Co.

$150.67 84,80% (12M)

P/E

114.53

2.29%

ROE

7.55%

P/BV

8.64

AZN - AstraZeneca

$162.57 1,38% (12M)

P/E

23.89

1.99%

ROE

20.74%

P/BV

4.95

PFE - Pfizer

$28.64 23,22% (12M)

P/E

35.72

6.28%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$917.36 34,14% (12 M)

P/L

20.12

0.37%

ROE

-137.16%

P/VP

-27.60

CAH - Cardinal Health

$247.79 67,79% (12 M)

P/L

35.62

0.87%

ROE

-57.93%

P/VP

-20.64

JNJ - Johnson & Johnson

$276.47 59,62% (12 M)

P/L

30.34

1.98%

ROE

24.76%

P/VP

7.51

ABBV - AbbVie

$257.20 24,86% (12 M)

P/L

72.02

2.66%

ROE

-106.44%

P/VP

-76.66

MRK - Merck & Co.

$150.67 84,80% (12 M)

P/L

114.53

2.29%

ROE

7.55%

P/VP

8.64

AZN - AstraZeneca

$162.57 1,38% (12 M)

P/L

23.89

1.99%

ROE

20.74%

P/VP

4.95

PFE - Pfizer

$28.64 23,22% (12 M)

P/L

35.72

6.28%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Alnylam Pharmaceuticals (ALNY) today?

A cotação de Alnylam Pharmaceuticals (ALNY) hoje está em US$ 265.23, com uma variação de -41.52% em relação ao último ano. A cotação de Alnylam Pharmaceuticals (ALNY) iniciou o ano negociando na casa dos US$ 397.65 e hoje está em US$ 265.23. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Alnylam Pharmaceuticals (ALNY) e dados de ações do Ibovespa e mercados internacionais.

Quando Alnylam Pharmaceuticals (ALNY) paga dividendos?

Alnylam Pharmaceuticals (ALNY) não distribuiu dividendos no último ano.

Is Alnylam Pharmaceuticals (ALNY) a good investment?

Atualmente, Alnylam Pharmaceuticals (ALNY) está cotada a US$ 265.23, com um P/L de 40.56, representando um desvio de -5,883% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -41.52 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -41.52%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Alnylam Pharmaceuticals (ALNY) stock?

Investir em ações de Alnylam Pharmaceuticals (ALNY) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Alnylam Pharmaceuticals (ALNY) yield today?

A rentabilidade de Alnylam Pharmaceuticals (ALNY) foi de 17.29% no último mês, -41.52% no último ano e 40.88% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Alnylam Pharmaceuticals (ALNY) hoje, o investimento total seria de US$ 26,523.00, com base na cotação atual de US$ 265.23.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 15,510.65
Em 5 anos: US$ 37,365.60
Em 10 anos: US$ 96,989.31

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ALNY

Alnylam Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ALNY

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING ALNY WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

United States

23 years

2004

1.453

PROFIT X PRICE ALNY

Financial Results ALNY

ALNY cash flow

Asset, Revenue and Profit Growth - ALNY

ALNY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions